In my practice, I am often sitting with people who are thinking ahead, quietly or urgently, about cognitive decline, family history, and what their future might hold. What Patrick Holford has brought forward in his recent summary of the research speaks directly into that space, where people are trying to make sense of what truly helps and where to place their energy. The Cochrane review he refers to, covering a large body of clinical trials on anti-amyloid drugs, points toward a consistent finding that the measurable impact on cognition and dementia severity remains minimal in terms of meaningful change for patients. This distinction between statistical movement and lived clinical difference is one that matters deeply when we are working with real people, real families, and the slow unfolding of neurological conditions.

What becomes particularly relevant is the shift in thinking around amyloid itself. The long-held narrative positioned amyloid as a central driver of Alzheimer’s disease, yet the interpretation emerging here is more nuanced, suggesting that amyloid may reflect a downstream process rather than the origin point. When we look through a functional and systems-based lens, this aligns with how many chronic conditions present in the body, where what is visible is often part of a broader adaptive or protective response. The suggestion that beta-amyloid may play a role in vascular integrity, including responses to micro-bleeds, invites a deeper consideration of the body’s intelligence rather than viewing it as simply malfunctioning.

The safety profile raised in these discussions also deserves careful attention. Reports of brain-related adverse effects in a proportion of trial participants highlight that interventions aimed at altering one pathway can carry consequences elsewhere. In clinical work, this reinforces the importance of understanding terrain, resilience, and the interconnected nature of systems, rather than focusing narrowly on a single target. It becomes less about suppressing a marker and more about understanding why that marker is present in the first place.

Where this conversation becomes far more constructive is in the area of prevention and modulation. The emphasis on B vitamins, omega-3 fatty acids, and broader lifestyle factors resonates strongly with what I see repeatedly in practice. When we explore methylation pathways, homocysteine levels, lipid metabolism, and inflammatory patterns through genetic and functional testing, there is often a clear narrative emerging around nutrient insufficiency, oxidative stress, and compromised repair mechanisms. These are not abstract concepts; they show up in fatigue, mood changes, cognitive slowing, and subtle shifts that precede more significant decline.

The role of the nervous system is central within this. Chronic stress patterns, dysregulated autonomic states, and long-standing emotional load all influence inflammation, vascular health, and neurochemical balance. When I am working with someone, I am not separating their cognitive health from their emotional landscape or their physiological history. The body carries patterns over time, and the brain reflects those patterns. Supporting regulation, improving sleep architecture, stabilising blood sugar, and addressing gut health all become part of a coherent strategy rather than isolated interventions.

Nutritional strategies highlighted in this discussion, including increasing intake of whole foods rich in essential fatty acids and phospholipids, reducing processed food exposure, and supporting micronutrient sufficiency, are entirely consistent with a preventative model that respects the body’s capacity for repair. When combined with targeted supplementation, informed by testing rather than guesswork, there is often a noticeable shift in how people feel and function. This is particularly evident in those in early or preclinical stages, where there is still significant capacity for change.

What I find most important in all of this is the direction of attention. When the focus moves toward supporting the system as a whole, rather than attempting to override a single pathway, the conversation changes. It becomes more grounded, more personalised, and far more responsive to the individual in front of me. The integration of genetics, functional markers, and psychotherapy allows for a layered understanding of why someone’s cognitive health is moving in a particular direction, and what can realistically be done to influence that trajectory.

This is where the real work sits. Not in broad generalisations, and not in isolated interventions, but in careful, detailed exploration of the person’s biology, history, and current state. From there, meaningful shifts can begin to take place, often in ways that feel both subtle and significant over time.

I am right here if you have any concerns about a parent, family member or you yourself. I am right here…